INVO vs. DYNT, RSLS, QNRX, TNON, OSAP, IONM, AEMD, GMVDF, AFIB, and BJDX
Should you be buying INVO Bioscience stock or one of its competitors? The main competitors of INVO Bioscience include Dynatronics (DYNT), ReShape Lifesciences (RSLS), Quoin Pharmaceuticals (QNRX), Tenon Medical (TNON), ProSomnus (OSAP), Assure (IONM), Aethlon Medical (AEMD), G Medical Innovations (GMVDF), Acutus Medical (AFIB), and Bluejay Diagnostics (BJDX). These companies are all part of the "surgical & medical instruments" industry.
INVO Bioscience (NASDAQ:INVO) and Dynatronics (NASDAQ:DYNT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk.
Dynatronics received 302 more outperform votes than INVO Bioscience when rated by MarketBeat users. Likewise, 50.82% of users gave Dynatronics an outperform vote while only 46.67% of users gave INVO Bioscience an outperform vote.
Dynatronics has higher revenue and earnings than INVO Bioscience. Dynatronics is trading at a lower price-to-earnings ratio than INVO Bioscience, indicating that it is currently the more affordable of the two stocks.
In the previous week, INVO Bioscience had 1 more articles in the media than Dynatronics. MarketBeat recorded 5 mentions for INVO Bioscience and 4 mentions for Dynatronics. INVO Bioscience's average media sentiment score of 0.45 beat Dynatronics' score of -0.26 indicating that INVO Bioscience is being referred to more favorably in the media.
12.0% of INVO Bioscience shares are held by institutional investors. Comparatively, 4.2% of Dynatronics shares are held by institutional investors. 3.5% of INVO Bioscience shares are held by insiders. Comparatively, 9.1% of Dynatronics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
INVO Bioscience has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Dynatronics has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.
Dynatronics has a consensus price target of $3.80, indicating a potential upside of 769.76%. Given Dynatronics' higher probable upside, analysts clearly believe Dynatronics is more favorable than INVO Bioscience.
Dynatronics has a net margin of -13.07% compared to INVO Bioscience's net margin of -459.42%. INVO Bioscience's return on equity of 0.00% beat Dynatronics' return on equity.
Summary
Dynatronics beats INVO Bioscience on 9 of the 16 factors compared between the two stocks.
Get INVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for INVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
INVO Bioscience Competitors List
Related Companies and Tools
